Mochi Health's GLP-1 Program: Structure, Options, Costs

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub, our home for GLP-1 science, weight-management protocols, and the genetics that shape metabolic outcomes. Visit the Peptides & GLP-1 hub.

This is an independent editorial review. PlexusDx has no commercial relationship with Mochi Health, earns nothing from mentioning it, and uses no affiliate links.

If you are looking into Mochi Health's GLP-1 program, the practical questions are how the service is organized, which medications tend to appear in a program like it, and what a prescription does — and doesn't — account for. This review lays that out with fair-balance framing rather than a recommendation, current as of April 2026.

Where Mochi Health sits in the GLP-1 landscape

Mochi Health (Mochi Health) runs as telehealth with insurance support. In practice that means a licensed provider conducts a virtual evaluation and, when appropriate, issues a prescription that routes to a retail pharmacy for FDA-approved brand medication or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. The current specifics are on Mochi Health's official website.

How the program is structured, step by step

A GLP-1 telehealth program generally moves through four stages: an intake capturing weight, history, and medications; a clinician's review and eligibility decision; routing of the prescription to a retail or compounding pharmacy; and ongoing follow-up for titration and side-effect support. Where programs differ is in provider type, pharmacy partner, and subscription terms — worth checking against Mochi's published details.

Which GLP-1 compounds appear in a program like this

The medications behind these programs are GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide — and the dual GIP/GLP-1 agonist tirzepatide. They influence appetite, satiety, and how quickly the stomach empties. Whether dispensed as branded product or compounded preparation, the compound is what determines the pharmacology, not the telehealth brand facilitating access.

What the trials established for the class

The evidence base belongs to the compounds. STEP examined semaglutide for weight management (NEJM, 2021), SURMOUNT looked at tirzepatide for the same purpose (NEJM, 2022), and SURMOUNT-OSA studied tirzepatide in obstructive sleep apnea (NEJM, 2024). Trial designs and endpoints differ, and outcomes vary from one person to the next.

What a GLP-1 telehealth program costs

Total monthly spend depends on the medication chosen, the subscription tier, and whether the product is branded or compounded, and figures change frequently — Mochi publishes its own on its site. Because Mochi builds in insurance support, coverage outcomes can vary by plan; compounded products, by contrast, are generally cash-pay.

The genetic layer a prescription doesn't capture

One thing no GLP-1 program screens for is the inherited biology under your response. An FTO variant influences appetite and body-weight set point, MC4R anchors satiety signaling, and GLP1R encodes the receptor every one of these compounds acts on. The PlexusDx Precision Peptide Genetic Test examines 14 pathways, 49 peptides, 150+ genetic insights across that biology — mapping context, not predicting how any single medication will perform for you.

How PlexusDx approaches it

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, with a flat-priced microdose option at $129/month among the choices. Paired with the Precision Peptide Genetic Test ($298, or $99 for program members), the model puts pathway data in front of the protocol — a test-before-you-invest sequence most telehealth-only programs leave out.

No affiliation: PlexusDx is independent of Mochi Health and has no commercial relationship with it.

Related PlexusDx reading: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, and What Is GLP 1.

Editorial note: this review is educational and independent. PlexusDx has no relationship with Mochi Health and provides semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways; it does not predict response to a specific medication. Talk with a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

What GLP-1 medications does a program like Mochi Health use?

Programs in this category typically work with GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, dispensed either as FDA-approved brand products or compounded preparations. The exact menu and eligibility rules are set by Mochi Health and posted on its own website, so confirm current options there.

Does Mochi Health work with insurance?

Mochi Health operates as telehealth with insurance support, which can affect what you pay depending on your plan. Compounded GLP-1 medications, however, are commonly cash-pay. Coverage varies widely, so review the current terms and any documentation requirements directly on Mochi Health's site before enrolling.

How is compounded semaglutide different from the branded drug?

Compounded semaglutide is prepared by a 503A pharmacy for an individual prescription, while the branded product is an FDA-approved medication dispensed at retail. The active pathway is the same GLP-1 mechanism, but sourcing, cost, and availability differ, which is why programs route prescriptions along one path or the other.

Can genetic testing improve a GLP-1 program?

The Precision Peptide Genetic Test does not predict how you will respond to a GLP-1 medication. It maps pathway-level variants like FTO, MC4R, and GLP1R that describe your metabolic baseline, giving you and your provider context to bring into decisions about any GLP-1 protocol.

This article is part of the PlexusDx Education Hub. Explore more Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.